成分分析·活性分析·代谢分析

ELISA法测定大鼠血浆中抗体偶联药物浓度及药代动力学研究

展开
  • 1.沈阳药科大学, 沈阳 110016;
    2.珠海市丽珠单抗生物技术有限公司, 珠海 519045
第一作者 Tel:13610820352; E-mail:yingpeng1999@163.com
* Tel:(0756)8135262; E-mail:815683714@qq.com

收稿日期: 2021-07-01

  网络出版日期: 2024-06-24

Determination of antibody-drug conjugate in rat plasma by ELISA and study of its pharmacokinetics

Expand
  • 1. Shenyang Pharmaceutical University, Shenyang 110016, China;
    2. Livzon Mabpharm Inc., Zhuhai 519045, China

Received date: 2021-07-01

  Online published: 2024-06-24

摘要

目的: 建立检测大鼠血浆中抗体偶联药物(ADC006M)[重组抗人表皮生长因子受体2(HER2)结构域Ⅱ人源化单克隆抗体-单甲基澳瑞他汀E(MMAE)偶联剂]浓度的酶联免疫吸附分析法(ELISA),并用于研究单次静脉注射的药代动力学特征。方法: 基于ELISA的检测原理,在96孔板上预先包被抗MMAE抗体,加入待测样品,用HRP标记的抗体B1G7(B1G7-HRP)进行检测,加入TMB底物显色,终止反应后,在酶标仪450 nm/630 nm波长处读取吸收度(A),并参考相关法规进行方法学验证。同时,单次静脉注射给予SD大鼠5 mg·kg-1ADC006M测定其血浆浓度,对测定结果进行曲线拟合并计算药代动力学参数。结果: 确定方法的线性范围为31.25~2 000 ng·mL-1,定量限为31.25 ng·mL-1;方法批内、批间准确度RE分别在-14.6%~12.6%和-13.1%~-0.7%,批内、批间精密度RSD均≤12.6%;方法的选择性(基质效应)、特异性、稀释线性与钩状效应以及各项稳定性考察结果均良好。通过对SD大鼠血浆样品进行浓度测定,获得ADC006M药代动力学参数,雌鼠、雄鼠的Cmax分别为(114 218±17 845)μg·L-1和(119 900±12 259)μg·L-1,AUC0-∞分别为(90 546±6 481)μg·L-1·d-1和(89 648±13 735)μg·L-1·d-1,t1/2分别为(1.46±0.33)d和(1.70±0.28)d。结论: 本文建立的检测大鼠血浆中ADC006M浓度的ELISA方法,特异性、准确度、精密度、稳定性等均符合生物制药临床前药代动力学研究指导原则要求,ADC006M在大鼠体内的药代动力学特征不存在性别差异,其与同类ADC药物的代谢特征基本一致,具有较好的药代动力学特性。

本文引用格式

彭嘉宝, 彭缨 . ELISA法测定大鼠血浆中抗体偶联药物浓度及药代动力学研究[J]. 药物分析杂志, 2022 , 42(6) : 1037 -1044 . DOI: 10.16155/j.0254-1793.2022.06.16

Abstract

Objective: To establish an enzyme-linked immunosorbent assay (ELISA) for the detection of the concentration of antibody-drug conjugate [ADC006M, recombinant anti-human epidermal growth factor receptor 2 (HER2) domain Ⅱ humanized monoclonal antibody-monomethylauristatin E (MMAE) conjugate] in rat plasma, and to study its pharmacokinetic characteristics of single intravenous injection. Methods: Based on the test principle of ELISA, 96-well plate was pre-coated with anti-MMAE antibody, after adding the samples, detected with HRP-labeled antibody B1G7 (B1G7-HRP). Then, TMB substrate solution was added for color display. After the reaction was quenched,the absorption(A)was read at double wavelength of 450 nm/630 nm by using a microplate reader. With reference to the relevant regulations, the method had been validated. Meanwhile, SD rats were given 5 mg·kg-1 ADC006M intravenously to determine the plasma concentration,and the curve fitting was performed tocalculate the pharmacokinetic parameters. Results: The linear range of the method was 31.25-2 000 ng·mL-1, with lower limit of quantitation (LLOQ) of 31.25 ng·mL-1. The accuracy RE of intra-assay and inter-assay were -14.6% to 12.6% and -13.1% to -0.7%. The intra- and inter- precision RSD were both ≤12.6%, respectively. The selectivity (matrix effect), specificity, dilution linearity, hook effect, and stability of the method were all good. The pharmacokinetic parameters of ADC006M were determined by plasma concentration of SD rats, the Cmax was (114 218±17 845) μg·L-1 for female and (119 900±12 259) μg·L-1 for male, respectively, AUC0-∞ was (90 546±6 481) μg·L-1·d-1and (89 648±13 735) μg·L-1·d-1, t1/2 was (1.46±0.33) d and (1.70±0.28) d, respectively. Conclusion: An ELISA method was established to detect the concentration of ADC006M in the plasma of SD rats,its specificity, accuracy, precision, stability and so on all conform to the requirements of the research guidelines of biological preclinical pharmacokinetics. There was no gender difference in the pharmacokinetic characteristics of ADC006M in SD rats. It is basically consistent with the metabolic characteristics of similar ADC drugs and has great pharmacokinetic characteristics.

参考文献

[1] 杨跃梅,张伯彦,黎燕,等. 靶向抗肿瘤抗体-药物偶联物研究进展[J].国际药学研究杂志,2014,41(1):45
YANG YM, ZHANG BY, LI Y, et al. Development of antibody-drug conjugates as targeted cancer therapeutics[J].J Int Pharm Res, 2014, 41(1):45
[2] SINGH R, SETIADY YY, PONTE J, et al. A new, triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells[J].Mol Cancer Ther, 2016, 15(6):1311
[3] 郁越,李恒宇,盛湲. 抗体偶联药物在乳腺癌治疗中的进展[J].世界临床药物,2019, 40(3):157
YU Y, LI HY, SHENG Y. Advances in antibody-drug conjugates in the treatment of breast cancer[J].World Clin Drug, 2019, 40(3): 157
[4] WU AM, SENTER PD. Arming antibodies: prospects and challenges for immunoconjugates[J].Nat Biotechnol, 2005, 23 (9):1137
[5] ALLEY SC, OKELEY NM, SENTER PD. Antibody-drug conjugates: targeted drug delivery for cancer[J].Curr Opin Chem Biol, 2010, 14(4):529
[6] TEICHER BA, CHARI RVJ. Antibody conjugate therapeutics: challenges and potential[J].Clin Cancer Res, 2011, 17(20):6389
[7] KAMATH AV, IYER S. Challenges and advances in the assessment of the disposition of antibody-drug conjugates[J].Biopharm Drug Dispos, 2016, 37(2):66
[8] 徐冉驰,苗红,郑剑恒. 抗体偶联药物吸收、分布、代谢、排泄和毒性特征及分析方法研究进展[J].中国新药杂志,2019, 28(9):1087
XU RC, MIAO H, ZHENG JH. Absorption, distribution, metabolism, excretion and toxicity of antibody-drug conjugates and its research progress on analytical approaches[J].Chin New Drug J, 2019, 28(9):1087
[9] 国家食品药品监督管理总局. 药物非临床药代动力学研究技术指导原则[EB/OL].(2014-05-13) [2020-10-03].https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20140513120 001448.html
NMPA. Guidance for Nonclinical Pharmacokinetics of Medicinal Products[EB/OL].(2014-05-13) [2020-10-03].https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20140513120 001448.html
[10] 陆宁,佟仲生. 抗体药物偶联物在乳腺癌中的研究进展[J].中国慢性病预防与控制,2021, 29(7): 535
LU N, TONG ZS. Advances in antibody-drug conjugates in breast cancer[J].Chin J Prev Control Chronic Dis, 2021, 29(7): 535
[11] 郭建军,高然,权腾飞,等. 抗体偶联药物的药代动力学研究进展[J].药学学报,2015, 50(10): 1203
GUO JJ, GAO R, QUAN TF, et al. Progress on pharmacokinetic study of antibody-drug conjugates[J].Acta Pharm Sin, 2015, 50(10): 1203
[12] 季双敏,王玉珠,杨进波. 抗体偶联药物的分子特点及其药代动力学研究考虑[J].中国临床药理学杂志,2021, 37(6): 777
JISM, WANG YZ, YANG JB. Characteristics and considerations for pharmacokinetics of antibody-drug conjugates[J].Chin J Clin Pharmacol, 2021, 37(6): 777
[13] PHILLIPS GDL, LI GM, DUGGER DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate[J].Cancer Res, 2008, 68(22): 9280
[14] JUNUTULA JR, FLAGELLA KM, GRAHAM RA, et al. Engineeredthio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer[J].Clin Cancer Res, 2010, 16(19): 4769
[15] EMA. Committee for Medicinal Products for Human Use(CHMP):Guideline on bioanalytical method validation[EB/OL].(2011-07-21) [2020-10-03].https://www.EMEA/CHMP/EWP/192217/2009
[16] 中华人民共和国药典2020年版. 四部[S].2020: 466
ChP 2020.Vol Ⅳ[S].2020: 466
文章导航

/